Pulmonary Vascular Disease Due to Plasma Cell Dyscrasia

[1]  Paul G. Williams,et al.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension , 2019, European Respiratory Journal.

[2]  M. Gertz.  Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018 , 2018, Blood Cancer Journal.

[3]  M. Bayliss,et al.  Light Chain (AL) Amyloidosis: The Journey to Diagnosis , 2017, The Patient - Patient-Centered Outcomes Research.

[4]  B. Barlogie,et al.  Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease , 2017, American journal of hematology.

[5]  A. Dispenzieri,et al.  Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response , 2017, Heart.

[6]  A. Dispenzieri,et al.  Clinical relevance of pulmonary amyloidosis: an analysis of 76 autopsy-derived cases , 2017, European Respiratory Journal.

[7]  M. Dhodapkar.  MGUS to myeloma: a mysterious gammopathy of underexplored significance. , 2016, Blood.

[8]  M. Dimopoulos,et al.  Recent advances in the management of AL Amyloidosis , 2016, British journal of haematology.

[9]  H. Mizuno,et al.  Pulmonary arterial hypertension due to pulmonary vascular amyloid deposition in a patient with multiple myeloma. , 2015, International journal of clinical and experimental pathology.

[10]  T. Mark,et al.  Pulmonary Hypertension Complicating Multiple Myeloma , 2015, Pulmonary circulation.

[11]  M. Lacy,et al.  Severe Reversible Pulmonary Hypertension in Smoldering Multiple Myeloma: Two Cases and Review of the Literature , 2015, Pulmonary circulation.

[12]  T. Kurihara,et al.  Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension. , 2014, Internal medicine.

[13]  Wei Zhang,et al.  Pulmonary hypertension in POEMS syndrome , 2013, Haematologica.

[14]  T. Therneau,et al.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study , 2010, The Lancet.

[15]  T. Therneau,et al.  Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. , 2008, Blood.

[16]  H. Bitterman,et al.  Pulmonary Hypertension and Amyloidosis—an Uncommon Association: A Case Report and Review of the Literature , 2007, Journal of General Internal Medicine.

[17]  R. Hoover,et al.  Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. , 2005, Blood.

[18]  T. Therneau,et al.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. , 2005, Blood.

[19]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.

[20]  D. Dingli,et al.  Pulmonary hypertension in patients with amyloidosis. , 2001, Chest.

[21]  D. Dahlin.  Primary amyloidosis, with report of six cases. , 1949, The American journal of pathology.